Psych Trial Halted After Death; Curbing Phone Addiction; Most Worried Racial Group

The FDA halted patient enrollment in a phase III trial of evenamide in treatment-resistant schizophrenia following the sudden death of a participant, Newron Pharmaceuticals said.

Magnetic seizure therapy achieved similar remission rates to electroconvulsive therapy in patients with bipolar depression, but was better tolerated and had less worsening of autobiographical memory, a randomized trial showed. (American Journal of Psychiatry)

What should a patient ask their doctor before starting a mental health drug? Time offered some suggestions.

People with poor mental health reported lower patient activation, worse care quality, and lower confidence in the health system, a global survey found. (PLOS Medicine)

Over 70% of call center leaders for the 988 suicide hotline said they’re understaffed, and about 90% reported difficulty acquiring resources for hiring. (JAMA Network Open)

The New York Times offered tips to curb phone addiction.

Roughly 70% of veteran hospitalizations for alcohol use disorder didn’t include medication treatment, a retrospective study found. (Annals of Internal Medicine)

Experts in JAMA Internal Medicine reviewed the treatment of anxiety in primary care.

The risk for developing a mental disorder was more than twice as high in cancer patients, Danish data showed. (British Journal of Cancer)

A new survey found that 44% of Asian Americans reported feeling worried, the highest rate among all racial groups in the U.S., according to the STAATUS Index.

Federal funding is ending for California’s mobile crisis response teams — licensed and trained first responders who address mental health crises — just as demand is surging; state and local officials are trying to figure out what to do next. (CalMatters)

A trial of adults with severe depression, anxiety, and low positive affect showed that 15 weeks of positive affect treatment led to greater clinical improvement than negative affect treatment. (JAMA Network Open)

Lumateperone (Caplyta) outperformed other adjunctive major depressive disorder treatments across four efficacy measures in a meta-analysis of 10 randomized trials, said maker Johnson & Johnson.